Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma

Modern Pathology

Volumn 24, Issue 8, 2011, Pages 1139-1145

  Kuhn, Elisabetta ^a   Meeker, Alan K ^a   Visvanathan, Kala ^a,b   Gross, Amy L ^b   Wang, Tian Li ^a,c   Kurman, Robert J ^a,c   Shih, Ie Ming ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

clear cell carcinoma; FISH; ovarian cancer; telomere

Indexed keywords

ARTICLE; CANCER GRADING; CANCER MORTALITY; CLEAR CELL CARCINOMA; CLINICAL FEATURE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; OVARY CARCINOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TELOMERE;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; TELOMERE; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 79961032045     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.67     Document Type: Article

References (40)

1. Gilks CB. Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma. J Oncol 2010;740968.
2. Cho KR, Shih IM. Ovarian cancer. Annu Rev Pathol Mech Dis 2009;4:287-313.
3. Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008;5:e232.
4. Shih I-M, Kurman RJ. Ovarian tumorigenesis-a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511-1518. (Pubitemid 38529752)
5. Shih Ie M, Kurman RJ. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 2005;11:7273-7279. (Pubitemid 41507684)
6. Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34:433-443.
7. Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010; 221:49-56.
8. Salani R, Kurman RJ, Giuntoli II R, et al. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer 2008;18: 487-491. (Pubitemid 351668307)
9. Kuo KT, Guan B, Feng Y, et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and highgrade carcinomas. Cancer Res 2009;69:4036-4042.
10. Grobelny JV, Kulp-McEliece M, Broccoli D. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway. Hum Mol Genet 2001;10:1953-1961. (Pubitemid 32910540)
11. Batista LF, Artandi SE. Telomere uncapping, chromosomes, and carcinomas. Cancer Cell 2009;15:455-457.
12. Meeker AK, Hicks JL, Iacobuzio-Donahue CA, et al. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res 2004;10:3317-3326. (Pubitemid 38685436)
13. Kuhn E, Meeker A, Wang TL, et al. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol 2010;34:829-836.
14. Meeker AK, De Marzo AM. Recent advances in telomere biology: implications for human cancer. Curr Opin Oncol 2004;16:32-38. (Pubitemid 38703469)
15. Counter CM, Hirte HW, Bacchetti S, Harley CB. Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA 1994;91:2900-2904. (Pubitemid 24130141)
16. Kyo S, Kanaya T, Takakura M, et al. Expression of human telomerase subunits in ovarian malignant, borderline and benign tumors. Int J Cancer 1999; 80(6):804-809. (Pubitemid 29108852)
17. Braunstein I, Cohen-Barak O, Shachaf C, et al. Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells. Cancer Res 2001;61:5529-5536. (Pubitemid 32694938)
18. Sun PM, Wei LH, Luo MY, et al. The telomerase activity and expression of hTERT gene can serve as indicators in the anti-cancer treatment of human ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2007;130:249-257.
19. Wang SJ, Sakamoto T, Yasuda Si S, et al. The relationship between telomere length and telomerase activity in gynecologic cancers. Gynecol Oncol 2002;84:81-84. (Pubitemid 34056471)
20. Aldea AI, Barnadas A, Tarrats A, et al. Analysis of telomeric length in epithelial carcinoma of the ovary. Med Clin (Barc) 1998;110:561-565. (Pubitemid 128526531)
21. Murakami J, Nagai N, Ohama K, et al. Telomerase activity in ovarian tumors. Cancer 1997;80:1085-1092. (Pubitemid 27427608)
22. Murakami J, Nagai N, Ohama K. Telomerase activity and telomere length as diagnostic tumor marker for ovarian tumors. Nippon Rinsho 1998;56:1310-1315.
23. Meeker AK, Gage WR, Hicks JL, et al. Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining. Am J Pathol 2002;160:1259-1268. (Pubitemid 34411630)
24. Chen C, Hong YK, Ontiveros SD, et al. Single base discrimination of CENP-B repeats on mouse and human Chromosomes with PNA-FISH. Mamm Genome 1999;10:13-18. (Pubitemid 29389936)
25. Veras E, Mao TL, Ayhan A, et al. Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. Am J Surg Pathol 2009;33:844-853.
26. Kim JH, Lee GE, Kim JC, et al. A novel telomere elongation in an adriamycin-resistant stomach cancer cell line with decreased telomerase activity. Mol Cells 2002;13:228-236. (Pubitemid 41583023)
27. Chan JK, Teoh D, Hu JM, et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 2008;109:370-376.
28. Ushijima K. Current status of gynecologic cancer in Japan. J Gynecol Oncol 2009;20:67-71.
29. Takano M, Kikuchi Y, Yaegashi N, et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 2006;94:1369-1374. (Pubitemid 43772268)
30. Mizuno M, Kikkawa F, Shibata K, et al. Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary. J Surg Oncol 2006;94: 138-143. (Pubitemid 44267195)
31. Jenison EL, Montag AG, Griffiths CT, et al. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol 1989;32:65-71. (Pubitemid 19029870)
32. Jones S, Wang TL, Shih IM, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010;330:228-231.
33. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363:1532-1543.
34. Kuo KT, Mao TL, Jones S, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009;174:1597-1601.
35. Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000;60: 7052-7056. (Pubitemid 32059184)
36. Ho CM, Lin MC, Huang SH, et al. PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas. Gynecol Oncol 2009;112:307-313.
37. Kuo K, Mao T, Feng Y, et al. DNA copy number profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res 2010;16:1997-2008.
38. Cerone MA, Londono-Vallejo JA, Autexier C. Telomerase inhibition enhances the response to anticancer drug treatment in human breast cancer cells. Mol Cancer Ther 2006;5:1669-1675. (Pubitemid 44323234)
39. Kobel M, Xu H, Bourne PA, et al. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol 2009;22:469-475.
40. Aoki D, Oda Y, Hattori S, et al. Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. Clin Cancer Res 2009;15:1473-1480.